Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PPOX | P50336 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | CASP9 | P55211 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6558629 | 0.87 | LMNA (0.70) | GAAPKML3MBTL1TDP1TSHR | |
| SCHEMBL7533766 | 0.87 | PPOX (0.56) | GAAPKML3MBTL1TDP1TSHR | |
| SCHEMBL13215132 | 0.81 | MAPK1 (0.52) | GAAPKML3MBTL1TDP1TSHR | |
| SCHEMBL3531540 | 0.81 | ALDH1A1 (0.56) | GAAPKML3MBTL1TDP1TSHR | |
| SCHEMBL31384765 | 0.81 | MAPK1 (0.52) | GAAPKML3MBTL1TDP1TSHR | |
| SCHEMBL15040809 | 0.80 | GAA (0.53) | GAAPKML3MBTL1TDP1TSHR | |
| SCHEMBL10646851 | 0.79 | LMNA (0.42) | GAAPKML3MBTL1TDP1TSHR | |
| SCHEMBL25658779 | 0.78 | NPC1 (0.61) | GAAL3MBTL1LMNAPPOXALDH1A1 | |
| SCHEMBL7561254 | 0.78 | PPOX (0.53) | GAAPKML3MBTL1TDP1TSHR | |
| SCHEMBL28001905 | 0.78 | GAA (0.53) | GAAPKMTDP1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767701-B2 | protein serine/threonine kinase inhibitors such as 2-(2-Chloro-5-fluoro-phenylimino)-5-(2,3-dihydro-benzo[1-6]dioxin-6-ylmethylene)-thiazolidin-4-one, used for treating autoimmune diseases, HIV, cancer, anemia myelodysplastic syndrome and thrombocytopenia | GLAXOSMITHKLINE LLC (US) | 2010-08-03 | — | — | US | disclosed |
| US-20090023742-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-01-22 | — | — | US | disclosed |
| EP-1993535-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-1567112-B1 | THIAZOLIDIN-4-ONES FOR INHIBITING hYAK3 PROTEINS | SMITHKLINE BEECHAM CORP (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007103754-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20060293338-A1 | Novel chemical compounds | GLAXOSMITHKLINE LLC | 2006-12-28 | — | — | US | disclosed |
| EP-1567112-A4 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1567112-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004047760-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293338-A1 | Novel chemical compounds | HIPK3, HIPK1, HIPK4 | GAA 770/4885PKM 3027/4885L3MBTL1 400/4885 |
| US-20090023742-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | PIK3CA, BTK, PI4KA | GAA 2041/4885PKM 539/4885L3MBTL1 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.